Insilico Medicine announced first-in-patient dosing of MEN2501, an oncology candidate discovered with generative AI, triggering a $5 million milestone payment from Menarini under their licensing pact. The company confirmed the Phase 1 dose in the trial and reported the contractual payment — a tangible validation of AI-driven discovery advancing into human testing. Separately, a Stanford spinout called Phylo secured backing from Menlo and a16z hours after its founders finished PhDs, signaling investor appetite for startups that bundle AI models with lab automation. The funding underscores venture capital momentum behind platform plays that aim to automate experimental science and accelerate candidate generation. Taken together, the transactions illustrate two industry moves: AI models progressing from in silico outputs to clinic-enabling assets, and venture investors financing AI-native teams to commercialize automated discovery pipelines. For drug developers, these events mark growing commercialization pathways for computational-first therapeutics and tools.